Positive results show delgocitinib cream improves chronic hand eczema in adolescents

Key takeaways:

• The study met the primary endpoint of a proportion of patients achieving IGA 0/1 at week 16 with at least a 2-point improvement from baseline.
• Further details will be presented at a later date.

The phase 3 DELTA TEEN trial evaluating Anzupgo 20 mg/g cream for the treatment of chronic hand eczema in adolescents has shown positive results, LEO Pharma announced in a press release.

The 16-week, randomized, double-blind, vehicle-controlled, phase 3 DELTA TEEN trial evaluated the efficacy and safety of twice-daily Anzupgo (delgocitinib, LEO Pharma) 20 mg/g cream, a topical pan-Janus kinase inhibitor, for the treatment of moderate to severe chronic hand eczema (CHE) in adolescents aged 12 to 17 years unable to use topical corticosteroids due to inadequate or inappropriate response.

There are currently no treatment options for this indication.

“Research on adolescents with CHE has revealed that the condition can considerably affect their quality of life, including psychosocial well-being, school performance and leisure activities,” Sonja Molin, MD, academic dermatologist at Charite Universitätsmedizin Berlin, adjunct associate professor of dermatology at Queen’s University and the coordinating investigator, said in the release. “These findings further our understanding of how moderate to severe CHE manifests in adolescents and how to support this underserved patient group.”

According to the release, the study met the primary endpoint of a proportion of patients achieving IGA 0/1 at week 16 with at least a 2-point improvement from baseline. The study also met all key secondary endpoints, validating the results of the previous clinical trials from the DELTA program, the release states.

The company plans to submit detailed results from DELTA TEEN for scientific presentation and publication at a coming date.